Erythromycin Stearate

Inquiry

Cat Number

API643221

CAS Number

643-22-1

For research use only. We do not supply to patients.

For pharmaceutical-grade products or other inquiries, please contact our experts.

Product Detail Description Advanced Innovations Customer Q&A

CAS Number

643-22-1

EINECS

211-396-1

Storage

2-8℃

Molecular Formula

C55H103NO15

Molecular Weight

1018.4

Smiles

CCCCCCCCCCCCCCCCCC(=O)O.CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O

Appearance

Solid

Melting Point

77-79℃

General Description

Erythromycin Stearate is the stearate salt of erythromycin, a macrolide antibiotic produced by Streptomyces erythreus. The stearate salt form exhibits improved acid stability and distinct solubility properties compared to the lactobionate salt, contributing to different absorption and bioavailability characteristics.

Mechanism of Action

Erythromycin reversibly binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step during translation. It prevents the transfer of the aminoacyl-tRNA from the A-site to the P-site of the ribosome, suppressing bacterial growth.

Application

Indicated for the treatment of upper and lower respiratory tract infections, skin infections, and pertussis caused by susceptible organisms. Erythromycin Stearate is a macrolide antibiotic with improved acid stability that provides reliable oral bioavailability for a broad range of community-acquired infections.

The pH-sensitive polymeric nanoparticles of Erythromycin Stearate were developed to improve oral bioavailability by protecting the drug from gastric acid and enhancing dissolution in intestinal pH. Nanoparticles were prepared using the solvent evaporation method with Eudragit L100-55 as the pH-sensitive polymer and polyvinyl alcohol (PVA) as a stabilizer. The optimized batch achieved a mean particle size of 513 nm, entrapment efficiency of 80.33%, and zeta potential of -22.4 mV. In vitro release showed only 8.24% release at pH 1.2 over 1 hour, but 90.38% release at higher pH (≥5.5) within 2 hours, indicating effective gastric protection and rapid intestinal release. Compared to a marketed enteric-coated tablet, the nanoparticles demonstrated superior release performance, with approximately 30% higher cumulative drug release. The release kinetics followed the Hixson-Crowell model in alkaline medium, suggesting dissolution-controlled release.

Fig. 2 Comparison of <i>in vitro</i> release profile of the Erythromycin Stearate nanoparticles with marketed product. (Bhadra S.; <i>et al</i>. 2016) Fig. 2 Comparison of in vitro release profile of the Erythromycin Stearate nanoparticles with marketed product. (Bhadra S.; et al. 2016)

References

Bhadra S, et al. Development of pH sensitive polymeric nanoparticles of erythromycin stearate. Journal of Pharmacy and Bioallied Sciences, 2016, 8(2): 135-140.

How does Erythromycin Stearate compare to Erythromycin Lactobionate in therapy?

Erythromycin Stearate offers improved acid stability for oral absorption, while Erythromycin Lactobionate provides enhanced water solubility for parenteral use, making them complementary for different clinical scenarios.

What storage conditions are required?

Should be stored at 2-8℃ in a tightly sealed container, protected from light and moisture.

What purity grade is available?

Supplied as a high-purity grade suitable for anti-infective R&D and pharmaceutical manufacturing.

Can packaging be customized?

Custom packaging options and order quantities can be tailored to customer R&D and production requirements.